Theracle is developing an implantable drug-device combination therapy for gliomas.
The approach uses an implantable drug-delivery device, bypassing the blood-brain barrier. The device will provide an ability to focus treatment directly at the cancer site using one or more drugs, and it is expected that treatment will result in no peripheral adverse effects. It is planned to pursue an FDA orphan drug designation, with fast-track status towards regulatory approval.
